Advancing Radioligand Candidates to Commercialisation Through Rigorous Clinical Rationale and Reliable Supply Chain Design

Success of prostate cancer treatments has triggered a seismic shift in the status of the TRP field over the last year and sparked more research investment than ever before.

The Targeted Radiopharmaceuticals Summit Europe returns for its fourth year as the only event to address the needs of drug developers at all development stages, from both medical and operational perspectives.

Overcome the technical, logistical, and translational hurdles of radionuclide therapy development. This event will bring together clinical, logistical and manufacturing experts from radiopharma and academia to help you accelerate your development programmes, tackle supply chain issues and harness alpha- and beta- emitting radionuclides to take on new cancers.